Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.5K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.5K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

8.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.0K
Cancer Therapies02:49

Cancer Therapies

8.9K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
8.9K
Cancer Vaccines01:30

Cancer Vaccines

600
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
600
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

5.4K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.4K
Tumor Immunotherapy01:27

Tumor Immunotherapy

801
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
801

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Bayesian networks as prognostic models in oncology: a systematic review and recommendations for clinical practice.

BMJ oncology·2026
Same author

Radiotheranostics in an evolving landscape: Emerging themes and considerations from a radiation therapy perspective.

Journal of medical imaging and radiation sciences·2026
Same author

Gene Expression in Muscle-Invasive and Non-Muscle-Invasive Bladder Cancer Cells Exposed to Hypoxia.

Cancers·2025
Same author

Cell Surface Proteomics Reveals Hypoxia-Regulated Pathways in Cervical and Bladder Cancer.

Proteomes·2025
Same author

Pelvic stereotactic ablative body radiotherapy (SABR) reirradiation: UK SABR consortium guidance for use in routine clinical care.

Technical innovations & patient support in radiation oncology·2025
Same author

Reirradiation: Standards, challenges, and patient-focused strategies across tumor types.

CA: a cancer journal for clinicians·2025
Same journal

MRI-enhanced online adaptive radiotherapy by virtual integration of a standalone MRI simulator and CBCT-based treatment delivery.

Radiation oncology (London, England)·2026
Same journal

Editorial expression of concern: Resveratrol enhances prostate cancer cell response to ionizing radiation. Modulation of the AMPK, Akt and mTOR pathways.

Radiation oncology (London, England)·2026
Same journal

Differential biological effects of scattered versus scanned clinical proton beams on Ewing sarcoma models.

Radiation oncology (London, England)·2026
Same journal

Impact of additional PRV constraint to Direct OAR robust optimization in IMPT for targets near serial organs at risk.

Radiation oncology (London, England)·2026
Same journal

Failure modes and effects analysis of LINAC-based stereotactic arrhythmia radioablation categorized by segmental targets.

Radiation oncology (London, England)·2026
Same journal

A rapid semi-automated trajectory planning method for non-coplanar interstitial brachytherapy in cervical cancer using a greedy algorithm.

Radiation oncology (London, England)·2026
See all related articles

Related Experiment Video

Updated: Nov 5, 2025

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
08:34

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Published on: February 6, 2019

20.7K

High dose simultaneous integrated boost for node positive cervical cancer.

Iresha Jayatilakebanda1, Yat Man Tsang1, Peter Hoskin2,3

  • 1Mount Vernon Cancer Centre, Rickmansworth Road, Northwood, Middlesex, HA6 2RN, UK.

Radiation Oncology (London, England)
|May 18, 2021
PubMed
Summary
This summary is machine-generated.

Simultaneous integrated boost (SIB) radiotherapy allows higher doses to abnormal lymph nodes in locally advanced cervical cancer. This approach shows promising survival outcomes without increased toxicity, potentially negating the negative impact of positive nodal status.

More Related Videos

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
04:04

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

10.7K
Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation
15:04

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Published on: January 19, 2019

12.5K

Related Experiment Videos

Last Updated: Nov 5, 2025

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
08:34

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Published on: February 6, 2019

20.7K
Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
04:04

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

10.7K
Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation
15:04

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Published on: January 19, 2019

12.5K

Area of Science:

  • Oncology
  • Radiotherapy
  • Gynecologic Oncology

Background:

  • Locally advanced cervical cancer with lymph node metastases indicates a poor prognosis.
  • Modern radiotherapy allows for escalated doses to abnormal lymph nodes.
  • This study evaluates treatment outcomes using a simultaneous integrated boost (SIB) policy.

Purpose of the Study:

  • To assess the efficacy and safety of SIB in treating locally advanced cervical cancer with positive lymph nodes.
  • To compare outcomes between patients receiving SIB and a control group with negative lymph nodes.
  • To determine the impact of SIB on overall survival, tumor response, and recurrence rates.

Main Methods:

  • Retrospective analysis of 69 patients with locally advanced cervical cancer treated with chemoradiation and SIB.
  • SIB delivered 60 Gy in 25 fractions to abnormal lymph nodes, alongside 45 Gy to the primary tumor.
  • Outcomes measured by overall survival (OS), local, regional, and distant recurrence-free survival (LRFS, RRFS, DRFS), and toxicity.

Main Results:

  • Complete response at 3 months was 100% for the primary tumor and 83% for SIB-treated nodal volumes.
  • Three-year OS, LRFS, RRFS, and DRFS for the SIB cohort were 69%, 91%, 79%, and 77%, respectively.
  • High doses were delivered to pelvic lymph nodes via SIB without significant increase in toxicity.

Conclusions:

  • SIB enables delivering 60 Gy in 25 fractions to abnormal pelvic nodes in cervical cancer with no added toxicity compared to node-negative patients.
  • High-dose SIB may overcome the adverse prognostic impact of positive nodal status.
  • Larger prospective studies are needed to validate these findings.